CENTOGENE and Takeda Boost Genetic Testing for LSDs
Company Announcements

CENTOGENE and Takeda Boost Genetic Testing for LSDs

Centogene N.V. (CNTG) has released an update.

CENTOGENE N.V., a key player in data-driven solutions for rare and neurodegenerative diseases, has announced the extension of its partnership with Takeda to enhance genetic testing accessibility for Lysosomal Storage Disorders (LSDs). This collaboration is set to improve diagnosis speeds and reliability for conditions such as Fabry disease, Gaucher disease, and Hunter syndrome. The agreement reinforces CENTOGENE’s commitment to providing essential diagnostic services and fostering global collaborations to advance treatment for rare disease patients.

For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCentogene NV Announces Nasdaq Delisting
TheFlyCentogene receives delisting notice from Nasdaq
TheFlyCentogene publishes ROPAD study data on Parkinson’s disease in Brain
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App